Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers.
Twenty-five patients with disseminated gastrointestinal malignancies were treated in a phase I study with a combination of ftorafur and mitomycin C or florafur and methyl-CCNU. Most patients had been heavily treated previously. Gastrointestinal, central nervous system, and marrow toxicity were manageable. Tumor regression was noted in five of 25 patients. A large-scale phase II study in untreated patients with gastrointestinal malignancies appears indicated with a combination of these agents.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001853:Bone Marrow / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D012673:Semustine / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
D008937:Mitomycins; D009607:Nitrosourea Compounds; D012673:Semustine; D005641:Tegafur; D005472:Fluorouracil